在同一组复发性前列腺癌患者的动态 PET/CT 评估中，比较[Ga]Ga-P16-093 和 [Ga]Ga-PSMA-617 的头对头比较。
Head-to-head comparison of [ Ga]Ga-P16-093 and [ Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients.
机构信息
Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
出版信息
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1052-1062. doi: 10.1007/s00259-021-05539-1. Epub 2021 Sep 23.
PURPOSE
This study was prospectively designed to evaluate the early dynamic organ distribution and tumor detection capability of [ Ga]Ga-P16-093, which was compared with [ Ga]Ga-PSMA-617 in the same group of recurrent prostate cancer patients.
METHODS
Twenty patients with recurrent prostate cancer were enrolled. In 2 consecutive days, each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of 148-185 MBq (4-5 mCi) [ Ga]Ga-P16-093 and [ Ga]Ga-PSMA-617, respectively. Following a low-dose CT scan, serial dynamic PET scans were performed from head to proximal thigh at 9 time points (30 s/bed at 4, 7, 10, 13, and 16 min; 1 min/bed at 20, 30, and 45 min; and 2 min/bed at 60 min). Standardized uptake values were measured for semi-quantitative comparison.
RESULTS
[ Ga]Ga-P16-093 PET/CT revealed a significantly higher tumor uptake at 4 min (SUVmax 7.88 ± 5.26 vs. 6.01 ± 3.88, P < 0.001), less blood pool retention at 4 min (SUVmean 5.12 ± 1.16 vs. 6.14 ± 0.98, P < 0.001), and lower bladder accumulation at 60 min (SUVmean 31.33 ± 27.47 vs. 48.74 ± 34.01, P = 0.042) than [ Ga]Ga-PSMA-617 scan. Significantly higher [ Ga]Ga-P16-093 uptakes were also observed in the parotid gland, liver, spleen, and kidney. Besides, [ Ga]Ga-P16-093 exhibited a better detectability of tumor than [ Ga]Ga-PSMA-617 (366 vs. 321, P = 0.009).
CONCLUSIONS
[ Ga]Ga-P16-093 showed advantages over [ Ga]Ga-PSMA-617 with higher tumor uptakes, tumor-to-blood pool ratio and detection capability, less blood pool, and bladder accumulation in recurrent prostate cancer patients.
TRIAL REGISTRATION
[ Ga]Ga-P16-093 and [ Ga]Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients (NCT04796467, Registered 12 March 2021, retrospectively registered) URL of registry: https://clinicaltrials.gov/ct2/show/NCT04796467.
目的
本研究前瞻性设计，旨在评估[68Ga]Ga-P16-093 在复发前列腺癌患者中的早期动态器官分布和肿瘤检测能力，并与同组患者中的[68Ga]Ga-PSMA-617 进行比较。
方法
共纳入 20 例复发前列腺癌患者。在连续 2 天内，每位患者分别在静脉注射 148-185MBq（4-5mCi）[68Ga]Ga-P16-093 和[68Ga]Ga-PSMA-617 后，进行 60min 动态 PET/CT 扫描。在进行低剂量 CT 扫描后，从头部到近端大腿进行连续 9 个时间点（4、7、10、13 和 16min 时每床位 30s；20、30 和 45min 时每床位 1min；60min 时每床位 2min）的动态 PET 扫描。进行标准化摄取值测量以进行半定量比较。
结果
[68Ga]Ga-P16-093 PET/CT 在 4min 时显示出更高的肿瘤摄取（SUVmax 7.88±5.26 比 6.01±3.88，P<0.001），4min 时的血池保留更少（SUVmean 5.12±1.16 比 6.14±0.98，P<0.001），60min 时膀胱积累更少（SUVmean 31.33±27.47 比 48.74±34.01，P=0.042），而[68Ga]Ga-PSMA-617 扫描则较低。在腮腺、肝脏、脾脏和肾脏中，也观察到更高的[68Ga]Ga-P16-093 摄取。此外，[68Ga]Ga-P16-093 比[68Ga]Ga-PSMA-617 显示出更好的肿瘤检测能力（366 比 321，P=0.009）。
结论
在复发前列腺癌患者中，[68Ga]Ga-P16-093 显示出优于[68Ga]Ga-PSMA-617 的优势，具有更高的肿瘤摄取、肿瘤与血池比值和检测能力，以及更少的血池和膀胱积累。
临床试验注册
[68Ga]Ga-P16-093 和 [68Ga]Ga-PSMA-617 在前列腺癌患者中的 PET/CT 成像（NCT04796467，2021 年 3 月 12 日注册，回顾性注册），网址：https://clinicaltrials.gov/ct2/show/NCT04796467。
Zotero 插件